Earnings Summary

Y-mabs Therapeutics Inc.’s revenue jumped 92.19% since last year same period to $20.75Mn in the Q2 2023. On a quarterly growth basis, Y-mabs Therapeutics Inc. has generated 2.47% jump in its revenue since last 3-months.

Y-mabs Therapeutics Inc.’s net profit jumped 84.68% since last year same period to $-6.3Mn in the Q2 2023. On a quarterly growth basis, Y-mabs Therapeutics Inc. has generated 1.38% jump in its net profits since last 3-months.

Y-mabs Therapeutics Inc.’s net profit margin jumped 92.03% since last year same period to -30.37% in the Q2 2023. On a quarterly growth basis, Y-mabs Therapeutics Inc. has generated 3.75% jump in its net profit margins since last 3-months.

Y-mabs Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.5 - a 29.58% jump from last quarter’s estimates.

Y-mabs Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -0.5.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Y-mabs Therapeutics Inc.’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Y-mabs Therapeutics Inc.’s return on equity (ROE) stands at -0.33.